share_log
Moomoo 24/7 ·  Feb 23 07:07
Travere Therapeutics And CSL Vifor Announced That The European Medicines Agency's CHMP Has Recommended Approval Of Sparsentan For Primary IgA Nephropathy With A Urine Protein Excretion >1.0 G/Day; European Commission Decision Is Expected In Q2 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment